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In vivo model confocal microscopy
SR101
Sulforhodaminea b s t r a c t
Sulforhodamine 101 (SR101) is a useful tool for immediate staining of astrocytes. We hypothesized that if
the selectivity of SR101was maintained in astrocytoma cells, it could prove useful for glioma research.
Cultured astrocytoma cells and acute slices from orthotopic human glioma (n = 9) and lymphoma
(n = 6) xenografts were incubated with SR101 and imaged with confocal microscopy. A subset of slices
(n = 18) were counter-immunostained with glial ﬁbrillary acidic protein and CD20 for stereological
assessment of SR101 co-localization. SR101 differentiated astrocytic tumor cells from lymphoma cells.
In acute slices, SR101 labeled 86.50% (±1.86; p < 0.0001) of astrocytoma cells and 2.19% (±0.47;
p < 0.0001) of lymphoma cells. SR101-labeled astrocytoma cells had a distinct morphology when com-
pared with in vivo astrocytes. Immediate imaging of human astrocytoma cells in vitro and in ex vivo
rodent xenograft tissue labeled with SR101 can identify astrocytic tumor cells and help visualize the
tumor margin. These features are useful in studying astrocytoma in the laboratory and may have clinical
applications.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Sulforhodamine 101 (SR101) is a red ﬂuorescent dye that has
been used in neuroscience research for the rapid and speciﬁc
labeling of astrocytes [1,2]. Its underlying mechanism is not
completely understood, but much like glial ﬁbrillary acidic pro-
tein (GFAP), SR101 labels astrocytic cells and has been used to
rapidly label rodent astrocytoma cells in culture [3]. If SR101
also labels glioblastoma (GBM) and other tumor cells of astrocy-
toma lineage, it could provide a more timely alternative to
GFAP for identifying astrocytoma cells in glioma models. Fur-
thermore, it may allow the rapid and deﬁnitive differentiation
of glioma from other tumors, such as lymphoma, during intra-
operative diagnosis. We aimed to establish whether the selec-
tive staining of astrocytic tumors by SR101 is a reliable and
reproducible method for rapidly identifying human astrocytomacells in cell culture and animal models, and to test this against
a negative control central nervous system (CNS) lymphoma ani-
mal model. We hypothesized that the combined use of live-cell
imaging with targeted ﬂuorophores could provide a rapid
method for conﬁrming the astrocytic lineage of tumors. If so,
SR101 may prove to be a rapid alternative to GFAP immunohis-
tochemistry in such models.2. Materials and methods
2.1. Cell culture
We acquired human glioma cell line U251 and human CNS
lymphoma cell line MC116 from American Type Culture Collection.
The cell lines were maintained in culture with Dulbecco’s Modiﬁed
Eagle Medium (DMEM) media supplemented with 10% fetal bovine
serum (FBS), and Roswell Park Memorial Institute (RPMI) 1640
media supplemented with 20% FBS (all from Invitrogen, Grand Is-
land, NY, USA). Cells were grown at 37C in a humidiﬁed incubator
under 5% CO2.
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U251 glioma cells were labeled by incubating 100,000 cells on a
collagen-coated glass-bottom dish (MatTek, Ashland, MA, USA).
After 24 hours, the mediumwas replaced with artiﬁcial cerebrospi-
nal ﬂuid (aCSF) containing 2 lM SR101 (Sigma-Aldrich, St Louis,
MO, USA) for 20 minutes, followed by two 5 minute washes with
standard aCSF.
2.3. Animals
Fifteen male Crl:NIH-Foxn1rnu rats (5 weeks of age) were ob-
tained from The Charles River Laboratories International (Wilming-
ton, MA, USA). Experiments were performed in accordance with
the guidelines and regulations set forth by the USA National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use Com-
mittee of the Barrow Neurological Institute of St. Joseph’s Hospital
and Medical Center, Phoenix, AZ, USA.
2.4. Intracranial implantation
Rats were anesthetized by intramuscular injection of a mixture
of 10 mg/kg xylazine and 80 mg/kg ketamine (Wyeth, Madison, NJ,
USA) and placed in a small animal stereotactic headframe (Model
900, David Kopf Instruments, Tujunga, CA, USA). A 10 mm incision
was made starting between the animal’s eyes to expose bregma. A
burr hole was made 3.5 mm lateral to bregma. U251 (nine rats) or
MC116 cells (six rats) were infused at a depth of 4.5 mm below the
surface of the brain after the syringe (Hamilton, Reno, NV, USA)
was advanced 5.0 mm to create a 0.5 mm pocket. The cell suspen-
sion was infused using a UMP3-1 UltraMicroPump microinjector
(WPI, Sarasota, FL, USA) set to a volume of 10 lL with an infusion
rate of 3 lL/minute. The needle was withdrawn 2 minutes after the
injection to minimize backﬂow of the cell suspension. The burr
hole was covered with bone wax, the skin incision was sutured,
and the rats were allowed to recover.
2.5. Acute slices
Twenty-eight days after implantation, rats were deeply anes-
thetized using the xylazine/ketamine mixture as described previ-
ously. They were immediately decapitated, and their brains were
removed. Immediately, coronal slices (350 lm thick) were cut
from the cerebral cortex on a Leica VT1200 vibratome (Leica Bio-
systems, Nussloch, Germany), in aCSF containing the following
(in mM): 126 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 MgSO4,
2 CaCl2 and 10 glucose, pH 7.4. Slices were then incubated at room
temperature in aCSF containing 2 lM SR101 for 20 minutes fol-
lowed by a 10 minute wash in aCSF. A two-tailed paired t-test with
alpha set to 0.05 was used to compare mean ﬂuorescence intensity
between tumor cells and reactive astrocytes.
2.6. Co-labeling
SR101 is not amenable to ﬁxation; we therefore used a ﬁxable
version of SR101 (Texas Red Hydrazide; Sigma-Aldrich) for these
experiments. The staining pattern of ﬁxable SR101 ﬂuorophore
mimics the staining pattern of the standard nonﬁxable SR101
[1,2]. For clarity, the use of the ﬁxable version of SR101 is clearly
indicated by the term ‘‘ﬁxable-SR101’’ throughout the text. Fix-
able-SR101 and the nonﬁxable version had similar staining pat-
terns, but the intensity and cellular staining of the ﬁxable version
was weaker than that of the standard SR101.
Acute xenograft slices were incubated with ﬁxable-SR101,
washed at room temperature, and ﬁxed with 4% paraformalde-hyde for 12 hours at 4C. The sections were rinsed in phosphate-
buffered saline, permeabilized with 0.3% Iriton, and blocked with
CAS block (Invitrogen) [4]. The GBM xenograft slices (nine slices
from three animals) were incubated in anti-GFAP primary anti-
body (EMD Millipore, Billerica, MA, USA; 1:500) for 12 hours,
and the lymphoma sections (nine slices from three animals) were
incubated in anti-CD20 primary antibody (EMD Millipore; 1:250)
for 12 hours. Sections were then rinsed and incubated with Alexa-
Fluor488 secondary antibody (Invitrogen), followed by 40,6-diami-
dino-phenylindole (DAPI; Invitrogen) nuclear counterstain and
mounted on slides with vectashield (Vector Laboratories, Burlin-
game, CA, USA) and number 1.5 coverslips (VWR, Radnor, PA,
USA).2.7. Stereology
We adapted standard stereology approaches to quantify tumor
cells labeled with ﬁxable-SR101 and GFAP or CD20 antibodies
[5,6]. We selected one rostral, midline, and caudal acute slice from
each brain containing tumor incubated with ﬁxable-SR101. Glioma
slices were immunoﬂuorescently stained for GFAP, and slices con-
taining lymphoma were stained for CD20. In each slice, 10 ran-
domly selected tumor regions (150 lm2) were optically sectioned
to 50 lm with a Zeiss 710LSM (Carl Zeiss Surgical, Oberkochen,
Germany). The ﬁrst 5 lm of each image stack was discarded to
minimize counts from cells damaged during sectioning. A maxi-
mum intensity projection image was generated from the remain-
ing 45 lm, and a stereology dissector was overlaid onto the
image. Cells within the dissector and those in contact with its left
and bottom edges were counted for either GFAP or CD20 positivity
and for SR101 positivity.
The percent overlap between immunostaining and SR101 posi-
tivity was calculated. Two-tailed t-tests with alpha levels of 0.05
were used to determine statistical differences. A paired t-test
was used to determine if staining localization between antibody
and SR101-labeling differed between cell types. An unpaired t-test
was used to compare ﬁxable-SR101 staining between glioma and
lymphoma models.2.8. Imaging
SR101-labeled samples were placed in uncoated number 1.5
glass-bottom dishes and positioned on the stage of a Zeiss 710
laser scanning confocal microscope equipped with a 40 /1.2 NA
water immersion objective (Carl Zeiss Surgical). We imaged
SR101 by exciting the ﬂuorophore with a 561 nm diode laser and
collecting 595 nm to 625 nm emissions. The confocal aperture
was set to one Airy unit for imaging. The laser and gain values were
set to ﬁll the dynamic range of the photomultiplier tube, and the
frame size was set to sample at Nyquist. Images were collected
in 8 and 12-bit format absent of nonlinear processing.2.9. Rapid uptake
To establish the time course of SR101 uptake, U251 astrocytoma
cells were visualized using the confocal microscope as previously
described. Astrocytoma cells were cultured on number 1.5 glass-
bottom dishes and placed on the stage of an inverted confocal
microscope. Time lapse images were collected 30 seconds prior
to addition of SR101 to 7 minutes post-incubation. Change in ﬂuo-
rescence intensity of astrocytoma cells and background was calcu-
lated with ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
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3.1. SR101 labels human astrocytoma cells and reactive astrocytes
To investigate the potential of SR101 for identifying human
astrocytoma cells, we used differential interference contrast with
ﬂuorescence overlay to image human astrocytoma cell line U251
after incubation in SR101 (six cultures). The ﬂuorophore ﬁlled
the cytoplasm of the cultured cells and clearly delineated cell
nuclei (Fig. 1A, B).
Next, human astrocytoma cells (U251 cell line) were implanted
into the caudate-putamen of six nude rats and allowed to grow for
4 weeks before the rats were sacriﬁced. This orthotopic xenograft
model consistently produced astrocytic tumors as previously char-
acterized [7,8]. Live cell confocal images of acute slices from the
cerebral cortex of the implanted animals (Fig. 1C) treated with
SR101 showed cells in the tumor core markedly labeled with the
ﬂuorophore. The cells were easily distinguished from low level
background staining (Fig. 1D–F).Fig. 1. Non-ﬁxable sulforhodamine 101 (SR101) labels human astrocytoma cells in
astrocytoma cell culture. (A) Differential interference contrast image with ﬂuorescent ove
of inset in (A) demonstrates cytoplasmic ﬁlling of cells and delineation of cell nuclei (arr
Acute slice containing U251 derived tumor. Representative core and margin regions iden
of SR101-labeled tumor core. (E) High magniﬁcation of inset in (D) shows typical morph
tumor core and background. Note the clear distinction in mean ﬂuorescence intensity (M
margin with SR101-labeled cells. (H) Inset of morphologically identiﬁed reactive astrocy
MFI of U251 cells and reactive astrocytes normalized to background (three acute slices fr
Scale bars = 20 lm. Used with permission from Barrow Neurological Institute.Confocal microscopy imaging of the acute slices treated with
SR101 also showed distinct tumor margins that contained SR101-
positive astrocytoma cells and reactive astrocytes (Fig. 1G, H).
The ﬂuorescence intensity from the astrocytoma cells and reactive
astrocytes was quantiﬁed. The mean ﬂuorescence intensity did not
differ between the two cell types (Fig. 1I). However, reactive astro-
cytes were easily distinguished based on their distinct morphology
(Fig. 1H). Therefore, SR101 can rapidly identify astrocytes and
astrocytoma cells in cell culture and animal models, and it can
effectively deﬁne tumor margins in an animal model.
3.2. Fixable-SR101 labels GFAP-positive human astrocytoma cells and
reactive astrocytes
We used confocal microscopy to compare the efﬁcacy and
localization of SR101 and GFAP staining. Confocal images from
the tumor core regions showed numerous cells simultaneously
ﬁlled with ﬁxable-SR101 and labeled by GFAP (Fig. 2A–D). In
general, GFAP and SR101 labeled the same cells, althoughculture and identiﬁes tumor core and margin in rodent xenografts. (A–B) U251
rlay of human U251 astrocytoma cells incubated with SR101. (B) High magniﬁcation
ows). (C–H) Acute slices from rodents intracranially implanted with U251 cells. (C)
tiﬁed by white circle and green circle, respectively. (D) Confocal ﬂuorescence image
ology of U251cells. (F) Histogram of SR101 ﬂuorescence distribution in (E) between
FI) between tumor (102.84) and background (8.74). (G) Image of acute slice tumor
te (arrow) surrounded by glioma cells (arrowheads) near tumor margin from (G). (I)
om three rats) showing no signiﬁcant difference in MFI between the two cell types.
Fig. 2. Fixable-sulforhodamine 101 (SR101) co-localizes with the astrocytic marker glial ﬁbrillary acidic protein (GFAP). (A) Confocal imaging of rodent xenograft acute slices
incubated in ﬁxable-SR101. Following incubation, slices were ﬁxed and stained with (B) GFAP and (C) 40 ,6-diamidino-phenylindole (DAPI). Images are from the core of the
astrocytoma. Fixable-SR101 ﬁlls the cell bodies of GFAP-positive cells in the tumor core and weakly ﬁlls astrocytic processes (arrows). (D) GFAP, DAPI and SR101 overlap
considerably in the merged image. (E–H) Images from the margin of the astrocytoma. Fixable-SR101 ﬁlls cell bodies of GFAP-positive cells at the tumor margin. Solid arrows
identify (E) SR101-positive and (F) GFAP-positive cells. Note the appearance of (G) DAPI positive cells (arrowheads) unlabeled by SR101 or GFAP that are selectively observed
at the astrocytoma margin. (H) Merged image from tumor margin. Scale bars = 20 lm. Used with permission from Barrow Neurological Institute.
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GFAP (Fig. 2A, B, D). Merged images from the tumor core showed
that most cells were positive for both ﬁxable-SR101 and GFAP,
indicating that SR101 effectively labels astrocytic tumor cells.
We compared the staining pattern of ﬁxable-SR101 and GFAP to
determine if reactive astrocytes could be differentiated from neo-
plastic astrocytes to help identify tumor borders. Imaging of rat
brain regions adjacent to human astrocytoma cells showed that
the staining patterns of ﬁxable-SR101 and GFAP were similar
(Fig. 2E, F). However, GFAP labeled membrane processes more
thoroughly than the ﬁxable-SR101. Cells in the peripheral regions
contained extensive membrane projections that could be readily
differentiated from cells within the tumor core that lacked this fea-
ture. When additional cells in these regions were stained with DAPI
(Fig. 2G), groups of cells were negative for both ﬁxable-SR101 and
GFAP (Fig. 2G, H). These ﬁndings suggest a mixed cell population of
tumor cells and nontumor brain cells typical of regions outside the
tumor core. Together, the data indicate that SR101-positive cells
are the GFAP-positive astrocytoma cell population. Furthermore,
ﬁxable-SR101 provides morphological information that appears
to differentiate astrocytoma cells from reactive astrocytes.3.3. SR101 differentiates astrocytoma from lymphoma
In contrast to the ﬁndings from astrocytoma cells, confocal
imaging indicated minimal SR101 signal from the human CNS
lymphoma cell line MC116 (Supp. Fig. 1). In acute slices from
astrocytoma and CNS lymphoma animal models incubated with
ﬁxable-SR101, we quantiﬁed co-localized GFAP for astrocytoma
slices and CD20 for lymphoma slices. In astrocytoma tumor
regions, ﬁxable-SR101 labeled the majority of cells (Fig. 3A–D, I).
The frequency of co-localization of SR101 and GFAP was 86.50%
(Fig. 3K, Table 1), with a mean of 22.30 SR101-positive cells and
20.58 GFAP-positive cells per stereology dissector region of inter-
est (ROI) (p = 0.0004, Fig. 3I, Table 1). In contrast, ﬁxable-SR101
labeled only a very small number of cells from ROI in CNS lym-
phoma acute slices (Fig. 3E). SR101 and CD20 co-localized poorly(2.19%), and there were signiﬁcantly more CD20-positive cells than
ﬁxable-SR101-positive cells (p < 0.0001) (Fig. 3J, Table 1). However,
SR101 labeled a small number of cells in CNS lymphoma tissue that
were not CD20-positive and that morphologically resembled reac-
tive astrocytes (Fig. 3E, F). SR101 distinguished astrocytoma from
lymphoma tissue and co-localized with GFAP more frequently than
CD20 (Fig. 3K). This ﬁnding demonstrates the strong relationship of
SR101 to GFAP-positive cells in astrocytoma, and the ability of
SR101 to differentiate an astrocytic from a non-astrocytic tumor
such as CNS lymphoma.
3.4. SR101 uptake is rapid
Astrocytoma cells exposed to SR101 in cell culture took up the
ﬂuorophore within 1 minute of incubation. One minute after incu-
bation, astrocytoma cells concentrated SR101 to approximately
twice the ﬂuorescence intensity of background, and within 3 min-
utes contained approximately six times the ﬂuorescence intensity
compared to background. These data show the utility of SR101
for rapidly labeling astrocytoma cells in culture (Supp. Fig. 2, 3).
4. Discussion
We have demonstrated a technique for identifying the most
common primary brain tumor, astrocytoma, in animal models by
ex vivo exposure to the ﬂuorescent agent SR101. We tested the
speciﬁcity of SR101 in human cell culture and orthotopic rodent
xenografts. We found SR101-labeling to be preserved in cell cul-
ture and animal models of astrocytoma. Compared to GFAP immu-
nocytochemistry, SR101 provided more rapid and equally accurate
identiﬁcation of astrocytic tumors. Our results clearly indicate the
potential utility of SR101 for rapidly identifying an astrocytic neo-
plasm. Compared to ex vivo tissue from a negative control animal
model, we found SR101 staining could differentiate astrocytoma
and CNS lymphoma within 30 minutes of biopsy. Our rapid incuba-
tion experiments in cell culture suggest that this time frame could
be compressed substantially further.
Table 1
Co-localization of immunostain-positive and sulforhodamine 101-positive cells from stereology
Tumor Immunostain Immunostain positive SR101 positive Percent overlap Total cells counted
Astrocytoma GFAP 20.58 ± 3.26 22.30 ± 3.55 86.50 ± 1.86 1316
Lymphoma CD20 25.61 ± 4.05 1.58 ± 0.32 2.20 ± 0.47 1657
GFAP = glial ﬁbrillary acidic protein, SR101 = sulforhodamine 101.
Data are presented as mean ± standard deviation.
Fig. 3. Sulforhodamine 101 (SR101) rapidly differentiates human astrocytoma from central nervous system (CNS) lymphoma in rodent xenografts. Confocal imaging of acute
slices from xenograft animals implanted with astrocytoma cells (U251, top row) or lymphoma cells (MC116, middle row). Slices were stained with ﬁxable-SR101 and speciﬁc
markers for astrocytoma, glial ﬁbrillary acidic protein (GFAP), or lymphoma (CD20). Nuclei were counterstained with 40 ,6-diamidino-phenylindole (DAPI). (A–D) Region from
U251 astrocytoma acute slice incubated with ﬁxable-SR101 and counterstained with GFAP and DAPI. (E) SR101 labels a single cell (arrow) in a MC116 xenograft lymphoma
region. (F) CD20 immunostaining labels lymphoma cells but does not label region containing SR101-positive cell (arrow). (G) DAPI counterstain of cell nuclei in ﬁeld of view.
(H) Merged lymphoma image indicating poor colocalization of SR101 and CD20. Scale bars = 20 lm. (I–K) Confocal stereology of acute slices. (I) Number of SR101-positive
cells slightly outnumber GFAP-positive cells in U251 xenograft astrocytoma regions (p = 0.0004). (J) Difference in number of SR101-positive and CD20-positive cells present in
MC116 xenograft lymphoma regions is highly signiﬁcant (p < 0.0001). (K) SR101 signiﬁcantly overlaps with GFAP-positive astrocytoma cells (86.50%) compared with CD20
lymphoma cells (2.19%, p < 0.0001). Used with permission from Barrow Neurological Institute. vs = versus.
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cause, compared to more invasive models, it is easier to distinguish
the border zone of the tumor and therefore distinguish tumor cells
from native astrocytes. In future studies, additional astrocytoma
models will need to be validated for their SR101 avidity.
U251 cells are largely GFAP-positive. GBM contains a heterozy-
gous population of cells that vary in terms of GFAP expression [9].
SR101 labeled slightlymore tumor cells in our GBM xenografts than
GFAP. This ﬁnding resembles data from normal brain showing that
SR101 identiﬁes subtypes of astrocytes and precursor cells that are
GFAP-negative [2,10]. Future studies on SR101 are needed to iden-
tify and characterizeGBMprecursor cells thatuptakeSR101.Adirect
comparison of the sensitivity of SR101 and GFAP in human brain
tumors obtained at surgery is being pursued by our group.
These ﬁndings have important implications for astrocytoma
research, since SR101 can be used to identify astrocytic tumor cells
in both in vitro and ex vivo settings in a more rapid time frame thanhas previously been possible. In addition, the fact that SR101-
labeling appears to occur within minutes could represent an
opportunity for clinical neuropathology, in that it could be used
intraoperatively to provide a deﬁnitive diagnosis that a given
tumor is of glioma lineage. While SR101 does not distinguish
astrocytoma from astrocytes (also a limitation of GFAP), it is
interesting that the selective uptake of SR101 is preserved in
malignant astrocytic cells. Further work is required to determine
the exact mechanism of uptake. Any variation in the uptake
mechanism between astrocytoma and astroctyes could represent
an opportunity for a selective therapy.5. Conclusion
SR101 rapidly and selectively labels human and rodent
astrocytic tumor cells. In an orthotopic xenograft model, SR101
J.F. Georges et al. / Journal of Clinical Neuroscience 21 (2014) 846–851 851staining retained its speciﬁcity. This method could provide utility
in neuro-oncology research. This technique also provides proof of
concept for a method to provide a clinically meaningful immediate
ex vivo neuropathological diagnosis.Conﬂicts of interest/disclosures
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